Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine if twice weekly 10 minute dilute bleach baths decreases disease severity in patients with moderate to severe atopic dermatitis.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01286220
Study type Interventional
Source University of Texas Southwestern Medical Center
Contact
Status Terminated
Phase N/A
Start date December 2010
Completion date August 2017

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT06012812 - A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis Phase 2
Completed NCT05549947 - Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis Phase 2
Recruiting NCT06136741 - A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis Phase 2
Recruiting NCT06099704 - Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis
Completed NCT03568162 - Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis Phase 2
Completed NCT00148746 - Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis N/A
Recruiting NCT05702268 - Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis Phase 2
Recruiting NCT05997927 - Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis Phase 2
Not yet recruiting NCT05197023 - A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS INJECTIONS OF SHR-1819 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS Phase 1
Not yet recruiting NCT06239311 - Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis. Phase 3
Completed NCT02426359 - Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients Phase 2